Omega-3-acid ethyl esters block the protumorigenic effects of obesity in mouse models of postmenopausal basal-like and claudin-low breast cancer

Cancer Prevention Research

Volumn 8, Issue 9, 2015, Pages 796-806

  Ford, Nikki A ^a   Rossi, Emily L ^b   Barnett, Kelsey ^a   Yang, Peiying ^c   Bowers, Laura W ^b   Hidaka, Brandon H ^d   Kimler, Bruce F ^d   Carlson, Susan E ^d   Shureiqi, Imad ^c   Degraffenried, Linda A ^a   Fabian, Carol J ^e   Hursting, Stephen D ^a,b  

^a University of Texas at Austin   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CLAUDIN; CYCLOOXYGENASE 2; ICOSANOID; LEPTIN; OMEGA 3 ACID ETHYL ESTER; SYNAPTOTAGMIN I; WNT PROTEIN; WNT1 PROTEIN; CLAUDIN 1; CLDN1 PROTEIN, MOUSE; ESTER; OMEGA 3 FATTY ACID; PTGS2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RELA; WNT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CLAUDIN LOW BREAST CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ERYTHROCYTE; FEMALE; GLUCOSE TOLERANCE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; MOUSE; NONHUMAN; OBESITY; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SERUM; TUMOR CELL LINE; ANIMAL; BLOOD; BODY COMPOSITION; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; CYTOLOGY; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; GLUCOSE TOLERANCE TEST; INFLAMMATION; METABOLISM; PILOT STUDY;

ADIPONECTIN; ANIMALS; BODY COMPOSITION; CELL LINE, TUMOR; CLAUDIN-1; CYCLOOXYGENASE 2; EICOSANOIDS; ERYTHROCYTES; ESTERS; FATTY ACIDS, OMEGA-3; FEMALE; GLUCOSE TOLERANCE TEST; INFLAMMATION; LEPTIN; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; OBESITY; PILOT PROJECTS; POSTMENOPAUSE; TRANSCRIPTION FACTOR RELA; WNT1 PROTEIN;

EID: 84941788268     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0018     Document Type: Article

References (47)

1. Hursting SD, Digiovanni J, Dannenberg AJ, Azrad M, Leroith D, Demark-Wahnefried W, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res 2012;5:1260-72.
2. Protani M, Coory M, Martin JH. Effect of obesity on survival of womenwith breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-635
3. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
4. Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer 2012;19:57-68.
5. Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, et al. Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10% weight loss in postmenopausal women. Breast Cancer Res Treat 2013;142:119-32.
6. Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. J Am Dietetic Assoc 2009;109:668-79.
7. Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci 2009;116:1-16.
8. Maillard V, Bougnoux P, Ferrari P, Jourdan ML, Pinault M, Lavillonniere F, et al. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. Int J Cancer 2002;98:78-83.
9. Kuriki K, Hirose K, Wakai K, Matsuo K, Ito H, Suzuki T, et al. Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese. Int J Cancer 2007;121:377-85.
10. Signori C, Du Brock C, Richie JP, Prokopczyk B, Demers LM, Hamilton C, et al. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. Eur J Clin Nutr 2012;66:878-84.
11. Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, et al. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res 2012;5:930-42.
12. Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PloS ONE 2012;7:e45831.
13. Hartman ZC, Poage GM, Den Hollander P, Tsimelzon A, Hill J, Panupinthu N, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 2013;73:3470-80.
14. Fabian CF, Kimler BF, Petroff BK, Zalles CM, Metheny T, Box JA, et al. Highdose omega-3 fatty acid (FA) supplementation modulates breast tissue biomarkers in pre-menopausal women at high risk for development of breast cancer. J Clin Oncol 2013;31:1515.
15. De Angel RE, Berrigan D, Nunez NP, Hursting SD, Perkins SN. Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. In Vivo 2009;23:527-35.
16. Lashinger LM, Malone LM, Brown GW, Daniels EA, Goldberg JA, Otto G, et al. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res 2011;4:1041-51.
17. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509.
18. Hidaka BH, Li S, Harvey KE, Carlson SE, Sullivan DK, Kimler BF, et al. Omega-3 and Omega-6 fatty acids in blood and breast tissue of high-risk women and association with atypical cytomorphology. Cancer Prev Res 2015;8:359-64.
19. Yee LD, Lester JL, Cole RM, Richardson JR, Hsu JC, Li Y, et al. Omega-3 fatty acid supplements in women at high risk of breast cancer have dosedependent effects on breast adipose tissue fatty acid composition. Am J Clin Nutr 2010;91:1185-94.
20. Yang P, Chan D, Felix E, Madden T, Klein RD, Shureiqi I, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COXand LOX-derived bioactive lipids. Prostaglandins Leukot Essent Fatty Acids 2006;75:385-95.
21. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
22. Gasparini C, Feldmann M. NF-κB as a target for modulating inflammatory responses. Curr Pharm Des 2012;18:5735-45.
23. Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, Chen Z, Oprea-Ilies G, et al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer 2013;13:537-43.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
25. Harris WS, Pottala JV, Sands SA, Jones PG. Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr 2007 86:1621-5.
26. Schuchardt JP, Schneider I, Meyer H, Neubronner J, Von Schacky C, Hahn A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis 2011;10:145.
27. Hoy SM, Keating GM. Omega-3 ethylester concentrate: a reviewof its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 2009;69:1077-105.
28. Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the U. S. J Diabetes 2010;2:180-93.
29. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol 2010;28:4058-65.
30. Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res 2009;2009:345320.
31. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006;26:968-76.
32. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
33. Rossmeisl M, Jilkova ZM, Kuda O, Jelenik T, Medrikova D, Stankova B, et al. Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PloS ONE 2012;7:e38834.
34. Dangardt F, Chen Y, Gronowitz E, Dahlgren J, Friberg P, Strandvik B. High physiological omega-3 fatty acid supplementation affects muscle fatty acid composition and glucose and insulin homeostasis in obese adolescents. J Nutr Metab 2012;2012:395757.
35. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med 2011;21:264-75.
36. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Diff 1999;6:99-104.
37. Hursting SD, Dunlap SM, Ford NA, Hursting MJ, Lashinger LM. Calorie restriction and cancer prevention: amechanistic perspective. CancerMetab 2013;1:10.
38. Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP, Grossman ME. Combination of intermittent calorie restriction and eicospentaenoic acid for inhibition of mammary tumors. Cancer Prev Res 2013;6:540-7.
39. Basu S, Nachat-Kappes R, Caldefie-Chezet F, Vasson MP. Eicosanoids and adipokines in breast cancer: from molecular mechanisms to clinical considerations. Antioxid Redox Signal 2013;18:323-60.
40. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res 2013;19:6074-83.
41. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99:1501-6.
42. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutation Res 2008;659:15-30.
43. Glueck CJ, Khan N, Riaz M, Padda J, Khan Z, Wang P. Titrating Lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy. Lipids Health Dis 2012;11:143.
44. Kimijima I, Ohtake T, Sagara H, Watanabe T, Takenoshita S. Scattered fat invasion: an indicator for poor prognosis in premenopausal, and for positive estrogen receptor in postmenopausal breast cancer patients. Oncology 2000;59:25-30.
45. Yamaguchi J, Ohtani H, Nakamura K, Shimokawa I, Kanematsu T. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. Am J Clin Pathol 2008;130:382-388.
46. Tan J, Buache E, Chenard MP, Dali-Youcef N, Rio MC. Adipocyte is a nontrivial, dynamic partner of breast cancer cells. Int J Dev Biol 2011;55:851-9.
47. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog 2013;52:446-58.